Jump to ContentJump to Main Navigation
Show Summary Details

Reviews on Environmental Health

Editor-in-Chief: Carpenter, David O. / Sly, Peter

Editorial Board Member: Brugge, Doug / Diaz-Barriga, Fernando / Edwards, John W. / Field, R.William / Hales, Simon / Horowitz, Michal / Maibach, H.I. / Shaw, Susan / Stein, Renato / Tao, Shu / Tchounwou, Paul B.

4 Issues per year


SCImago Journal Rank (SJR) 2015: 0.776
Source Normalized Impact per Paper (SNIP) 2015: 0.676
Impact per Publication (IPP) 2015: 1.795

Online
ISSN
2191-0308
See all formats and pricing
Volume 30, Issue 4 (Dec 2015)

Issues

Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians

Alison C. Bested
  • Corresponding author
  • Department of Medicine, University of British Columbia, Vancouver, BC, Canada
  • Email:
/ Lynn M. Marshall
  • Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
Published Online: 2015-11-27 | DOI: https://doi.org/10.1515/reveh-2015-0026

Abstract

This review was written from the viewpoint of the treating clinician to educate health care professionals and the public about Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It includes: the clinical definition of ME/CFS with emphasis on how to diagnose ME/CFS; the etiology, pathophysiology, management approach, long-term prognosis and economic cost of ME/CFS. After reading this review, you will be better able to diagnose and treat your patients with ME/CFS using the tools and information provided. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, chronic medical condition characterized by symptom clusters that include: pathological fatigue and malaise that is worse after exertion, cognitive dysfunction, immune dysfunction, unrefreshing sleep, pain, autonomic dysfunction, neuroendocrine and immune symptoms. ME/CFS is common, often severely disabling and costly. The Institute of Medicine (IOM) reviewed the ME/CFS literature and estimates that between 836,000 and 2.5 million Americans have ME/CFS at a cost of between 17 and 24 billion dollars annually in the US. The IOM suggested a new name for ME/CFS and called it Systemic Exertion Intolerance Disease (SEID). SEID’s diagnostic criteria are less specific and do not exclude psychiatric disorders in the criteria. The 2010 Canadian Community Health Survey discovered that 29% of patients with ME/CFS had unmet health care needs and 20% had food insecurity – lack of access to sufficient healthy foods. ME/CFS can be severely disabling and cause patients to be bedridden. Yet most patients (80%) struggle to get a diagnosis because doctors have not been taught how to diagnose or treat ME/CFS in medical schools or in their post-graduate educational training. Consequently, the patients with ME/CFS suffer. They are not diagnosed with ME/CFS and are not treated accordingly. Instead of compassionate care from their doctors, they are often ridiculed by the very people from whom they seek help. The precise etiology of ME/CFS remains unknown, but recent advances and research discoveries are beginning to shed light on the enigma of this disease including the following contributors: infectious, genetic, immune, cognitive including sleep, metabolic and biochemical abnormalities. Management of patients with ME/CFS is supportive symptomatic treatment with a patient centered care approach that begins with the symptoms that are most troublesome for the patient. Pacing of activities with strategic rest periods is, in our opinion, the most important coping strategy patients can learn to better manage their illness and stop their post-exertional fatigue and malaise. Pacing allows patients to regain the ability to plan activities and begin to make slow incremental improvements in functionality.

This article offers supplementary material which is provided at the end of the article.

Keywords: case definition; chronic fatigue syndrome; myalgic encephalomyelitis; pathophysiology and treatment; SEID

References

  • 1.

    Parlor M. Canadian Institutes of Health Research funding for research into chronic conditions, Quest 101, National ME/FM Action Network, Winter 2014:3.

  • 2.

    Brurberg KG, Fonhus MS, Larun L, Flottorp S. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open 2014;4:e003973.

  • 3.

    Carruthers BM, Jain AK, De Meirleir KL, Peterson D, Klimas NG, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatments protocols. J Chronic Fatigue Synd 2003;11(1):7–115. [Crossref]

  • 4.

    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, et al. The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Int Med 1994;121(12):953–9. [Crossref]

  • 5.

    Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988;108:387–9. [Crossref]

  • 6.

    Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, et al. Myalgic encephalomyelitis: international consensus criteria. J Int Med 2011;270:327–38. [Crossref]

  • 7.

    Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, et al. A report – chronic fatigue syndrome: guidelines for research. J Royal Society Med 1991;84:118–21.

  • 8.

    IOM (Institute of Medicine). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies, 2015:282pp.

  • 9.

    Jason LA, Sunnquist M, Kot B, Brown A. Unintended consequences of not specifying exclusionary illnesses for systemic Exertion Intolerance Disease. Diagnostics 2015;5:272–86. [Crossref]

  • 10.

    Jason LA, Sunnquist M, Brown A, Newton JL, Strand EB, et al. Chronic fatigue syndrome versus systemic exertion intolerance disease. Fatigue 2015;3:127–41.

  • 11.

    Jason L, Sunnquist M, Brown A, McManimen S, Furst J. Reflections on the IOM’s systemic exertion intolerance disease. Pol Arch Med Wewn 2015;576–80. pii: AOP_15_067.

  • 12.

    Brown AA, Jason LA. Validating a measure of myalgic encephalomyelitis/chronic fatigue syndrome symptomatology. Fatigue Biomed Health Behav 2014;2:132–52. [Crossref]

  • 13.

    McHorney CA, Ware JE, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993;31(3):247–63. [Crossref]

  • 14.

    Jason, LA, Evans M, Porter N, Brown M, Brown A, et al. The development of a revised Canadian myalgic encephalomyelitis chronic fatigue syndrome case definition. Am J Biochem Biotech 2010;6(2):120–35. [Crossref]

  • 15.

    Friedberg F, Bateman L, Bested A, Davenport T, Friedman K, et al. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis ME/CFS: primer for clinical practitioners. Chicago, IL: IACFS/ME. 2014:50pp.

  • 16.

    Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, et al. A community-based study of chronic fatigue syndrome. Arch Int Med 1999;159(18):2129–37. [Crossref]

  • 17.

    Bierl C, Nisenbaum R, Hoaglin DC, Randall B, Jones AB, et al. Regional distribution of fatiguing illnesses in the United States: a pilot study. Popul Health Metr 2004;2(1):1. [Crossref]

  • 18.

    Halapy E, Parlor, M. The Quantitative Data: Environmental Sensitivities/Multiple Chemical Sensitivity (ES/MCS), Fibromyalgia (FM), Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS), October 2013. http://www.meao.ca/files/Quantitative_Data_Report.pdf.

  • 19.

    Levine PH. Epidemic neuromyasthenia and chronic fatigue syndrome: epidemiological importance of a cluster definition. Clin Infect Dis 1994;18 Suppl 1:S16–20.

  • 20.

    Reyes M, Gary HE Jr, Dobbins JG, Randall B, Steele L, et al. Descriptive epidemiology of chronic fatigue syndrome: CDC surveillance in four US cities, September 1989 through August 1993. Morbid Mortal Week Report Surveil Sum 1997;46(SS–2):1–13.

  • 21.

    Reeves WC, Jones JF, Maloney E, Heim C, Hoaglin DC, et al. Prevalence of chronic fatigue syndrome in metropolitan, urban, and rural Georgia. Popul Health Metr 2007;5:5.

  • 22.

    Jason LA, Barker K, Brown A. Pediatric myalgic encephalomyelitis/chronic fatigue syndrome. Rev Health Care 2012;3(4):257–70. [Crossref]

  • 23.

    Nisenbaum R, Jones A, Jones J, Reeves W. Longitudinal analysis of symptoms reported by patients with chronic fatigue syndrome. Ann Epi 2000;10(7):458. [Crossref]

  • 24.

    Reynolds KJ, Vernon SD, Bouchery E, Reeves WC. The economic impact of chronic fatigue syndrome. Cost Effect Res Alloc 2004;2:4.

  • 25.

    Cairns RH. Systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (Oxford, England) 2005;55(1):20–31.

  • 26.

    March D. The Natural Course of Chronic Fatigue Syndrome: Evidence from a Multi-Site Clinical Epidemiology Study. Presentation IACFS San Francisco Conference 2014.

  • 27.

    Brown MM, Bell DS, Jason LA, Christos C, Bell DE. Understanding long-term outcomes of chronic fatigue syndrome. J Clin Psychol 2012;68(9):1028–35. [Crossref]

  • 28.

    Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. Q J Med 1997;90(3):223–33. [Crossref]

  • 29.

    Ciccone DS, Chandler HK, Natelson BH. Illness trajectories in the chronic fatigue syndrome: a longitudinal study of improvers versus non-improvers. J Nerv Ment Dis 2010;198(7):486–93. [Crossref]

  • 30.

    Pheby D, Saffron L. Risk factors for severe ME/CFS. Biol Med 2009;1(4):50–74.

  • 31.

    Bell DS. Twenty-five year follow-up in chronic fatigue syndrome: Rising Incapacity. Mass CFIDS Assoc. Continuing Education Lecture April 16, 2011.

  • 32.

    Rusu C, Gee ME, Lagacé C, Parlor M. Chronic fatigue syndrome and fibromyalgia in Canada: prevalence and associations with six health status indicators. Health Prom Chron Dis Prev Can 2015;35(1):3–11.

  • 33.

    Jason L, Corradi K, Gress S, Williams S, Torres-Harding S. Causes of death among patients with chronic fatigue syndrome. Health Care for Wom Int 2006;27(7):615–26.

  • 34.

    Smith WR, Noonan C, Buchwald D. Mortality in a cohort of chronically fatigued patients. Psych Med 2006;36(9):1301–6. [Crossref]

  • 35.

    Jason LA, Barker K, Brown A. Pediatric myalgic encephalomyelitis/chronic fatigue syndrome. Rev Health Care 2012;3(4):257–70. [Crossref]

  • 36.

    Jason LA, Katz BZ, Shiraishi Y, Mears C, Im Y, et al. Predictors of post-infectious chronic fatigue syndrome in adolescents. Heal Psych Behav Med 2014;2(1):41–51. [Crossref]

  • 37.

    Bell DS, Jordan K, Robinson M. Thirteen-year follow-up of children and adolescents with chronic fatigue syndrome. Pediatrics 2001;107(5):994–8.

  • 38.

    Rowe KSKJ. Symptom patterns in children and adolescents with chronic fatigue syndrome. In: Singh NN, Ollendick TH, Singh AN, editors. International Perspectives on Child and Adolescent Mental Health: Selected Proceedings of the Second International Conference on Child & Adolescent Mental Health, Kuala Lumpur, Malaysia, June 2000;2:395–422.

  • 39.

    Taylor RR, Kielhofner GW. Work-related impairment and employment-focused rehabilitation options for individuals with chronic fatigue syndrome: A review. J Mental Health 2005;14(3):253–267. [Crossref]

  • 40.

    Crawley EM, Emond AM, Sterne JAC. Unidentified chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a major cause of school absence: surveillance outcomes from school-based clinics. BMJ Open 2011;1(2):e000252. [Crossref]

  • 41.

    Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S. The economic impact of ME/CFS: Individual and societal costs. Dynamic Med 2008;7:6.

  • 42.

    Jason L, Torres-Harding S, Njok M. The face of CFS in the U.S. CFIDS Chronicle 2006;16–21. http://www.researchgate.net/profile/Leonard_Jason/publication/236995875.

  • 43.

    Solomon L, Reeves WC. Factors influencing the diagnosis of chronic fatigue syndrome. Arch Int Med 2004;164(20):2241–5. [Crossref]

  • 44.

    Hickie IB, Hooker AW, Hadzi-Pavlovic D, Bennett BK, Wilson AJ, et al. Fatigue in selected primary care settings: Sociodemographic and psychiatric correlates. Med J Australia 1996;164:585–8.

  • 45.

    Friedberg F, Bateman L, Bested A, Davenport T, Friedman K, et al. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis ME/CFS: Primer for clinical practitioners. Chicago, IL: IACFS/ME, 2014:16pp.

  • 46.

    Ware JE. SF-36 Health Survey. In Chronic fatigue and chronic fatigue syndrome: A co-twin control study of functional status. Qual Life Res 2002;11:463–71.

  • 47.

    Jason LA, Brown MM. Sub-typing daily fatigue progression in chronic fatigue syndrome. J Mental Health 2013;22(1):4–11. [Crossref]

  • 48.

    Lowenstein O, Feinberg R, Loewenfeld IE. Pupillary movements during acute and chronic fatigue. Invest Ophthal Visual Sci 1963;(2):138–57.

  • 49.

    Albright F, Light K, Light A, Bateman L, Cannon-Albright LA. Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC Neurology 2011;11:62.

  • 50.

    Underhill R, O’Gorman R. The prevalence of Chronic Fatigue Syndrome and chronic fatigue among family members of CFS patients. J CFS 2006;13(1):3–13.

  • 51.

    Buchwald D, Buchwald D, Hererell R, Ashton BS, Belcourt M, et al. A twin study of chronic fatigue. Psychosomatic Med 2001;63:936–43. [Crossref]

  • 52.

    Schur E, Afari N, Goldberg J, Dedra B, Sullivan PF. Twin analyses of fatigue. Twin Res Hum Genet 2007;10(5):729–33. [Crossref]

  • 53.

    Hickie IB, Bansal AS, Kirk KM, Lloyd AR, Martin, NG. A twin study of the etiology of prolonged fatigue and immune activation. Twin Res 2001;4(2):94–102. [Crossref]

  • 54.

    Kaiser J, Biomedicine. Genes and chronic fatigue: how strong is the evidence? Science 2006;312(5774):669–71. [Crossref]

  • 55.

    Kerr JR, Burke B, Petty R, Gough J, Fear D, et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol 2008;61(6):730–9.

  • 56.

    Shimosako N, Kerr JR. Use of single-nucleotide polymorphisms (SNPs) to distinguish gene expression subtypes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Clin Pathol 2014;67(12):1078–83. [Crossref]

  • 57.

    Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, et al. Infection Outcomes Study. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. Br Med J 2006;333(7568):575. [Crossref]

  • 58.

    Naess H, Nyland M, Hausken T, Follestad I, Nyland H. Chronic fatigue syndrome after giardia enteritis: Clinical characteristics, disability and long-term sickness absence. BMC Gastroenterology 2012;12:13.

  • 59.

    Mørch K, Hanevik K, Rivenes AC, Bødtker JE, Næss H, et al. Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course. BMC Gastroenterology 2013;13(28):1–8.

  • 60.

    Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome following infectious mononucleosis in adolescents. Pediatrics 2009;124(1):189–93. [Crossref]

  • 61.

    Siegel SD, Antoni MH, Fletcher MA, Maher K, Segota MC, et al. Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: Preliminary evidence for a subgroup? J Psychosom Res 2006;60(6):559–66. [Crossref]

  • 62.

    Hornig M, MOntoya JG, Klimas NG, Levine S, Felsenstein D, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 2015;1:e1400121. [Crossref]

  • 63.

    Bonecchi R, Bianchi G, Bordignon PP, D’Ambrosio D, Lang R, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1’s) and Th2’s. J. Exp. Med 1998;187:129–34.

  • 64.

    Arestides RS, He H, Westlake RM, Chen AI, Sharpe AH, et al. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol 2002;32: 2874–80.

  • 65.

    Simpson CR, Anderson WJ, Helms PJ, Taylor MM, Watson L, et al. Coincidence of immune-mediated disease driver by Th1 and Th2 subsets suggests a common aetiology. A population based study using computerized general practice data. Clin Exp All: J Br Soc Allergy Clin Immunol 2002;32(1):37–42. [Crossref]

  • 66.

    Torres-Harding S, Matthew Sorenson M, Jason LA, Kevin Maher K, Fletcher MA. Evidence for T-helper 2 shift and association with illness parameters in chronic fatigue syndrome (CFS). Bull IACFS ME 2008;16(3):19–33.

  • 67.

    Chris R, De Meirleir K. Self-test monitoring of the Th1/Th2 balance in health and disease with special emphasis on chronic fatigue syndrome/myalgic encephalomyelitis. J Med Lab Diagn 2012;3(1):1–6.

  • 68.

    Fletcher MA, Zeng XR, Barnes Z, Leivs S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009;7:96.

  • 69.

    Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, et al. Biomarkers in chronic fatigue syndrome: Evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS ONE 2010;5(5):e10817. [Crossref]

  • 70.

    Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28(6):1403–10.

  • 71.

    Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immun 2014;26(4):233–42. [Crossref]

  • 72.

    Hardcastle SL, Brenu EW, Johnston S, Nguyen T, Huth T, et al. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). BMC Immunology 2015;16:35.

  • 73.

    Broderick G, Fuite J, Kreitz A, Vernonb SD, Klimas N, et al. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010;24(7):1209–17. [Crossref]

  • 74.

    White AT, Light AR, Hughen RW, Bateman L, Thomas B, et al. Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology 2010;47(4):615–24.

  • 75.

    Stringer EA, Baker KS, Carroll IR, Montoya JG, Chu L, et al. Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. J Translat Med 2013;11:93.

  • 76.

    Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an 11C-(R)-PK11195 PET study. J Nucl Med 2014;55:945–50. [Crossref]

  • 77.

    Morris G, Berk M, Walder K, Maes M. Central pathways causing fatigue in neuroinflammatory and autoimmune illnesses BMC Med 2015;13:28.

  • 78.

    Suhadolnik RJ, Peterson DL, O’Brien K, Cheney PR, Herst CV, et al. Biochemical evidence for a novel low molecular weight 2–5A dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 1997;17:377–85. [Crossref]

  • 79.

    Gaber T, Oo WW. Prevalence of hypothyroidism in chronic fatigue syndrome patients. J Neuro 2013;260:S98–9.

  • 80.

    Friedberg F, Bateman L, Bested A, Davenport T, Friedman K, et al. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis ME/CFS: Primer for clinical practitioners. Chicago, IL: IACFS/ME, 2014:22pp.

  • 81.

    Keller BA, Pryor JL, Giloteaux L. Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2 peak indicates functional impairment. J Translat Med 2014;12(1):104.

  • 82.

    Davenport TE, Stevens SR, Baroni K, Van Ness M, Snell CR. Diagnostic accuracy of symptoms characterizing chronic fatigue syndrome. Dis Rehab 2011;33(19–20):1768–75.

  • 83.

    Cockshell SJ, Mathias JL. Cognitive functioning in people with chronic fatigue syndrome: A comparison between subjective and objective measures. Neuropsychology 2014;28(3):394–405. [Crossref]

  • 84.

    VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR. Postexertional malaise in women with chronic fatigue syndrome. J Wom Health 2010;19(2):239–44. [Crossref]

  • 85.

    Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med 2010;11:8:93.

  • 86.

    Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009;2(1):1–16.

  • 87.

    Whistler T, Toni Whistler T, James F, Jones JF, Elizabeth R, et al. Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol 2005;24;5(1):5.

  • 88.

    Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis 2014;29(1):19–36. [Crossref]

  • 89.

    Wong R, Lopaschuk G, Zhu G, Walker F, Catellier F, et al. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest 1992;102(6):1716–22. [Crossref]

  • 90.

    Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Int J Clin Exp Med 2012;5(3):208–20.

  • 91.

    Behan WMH, More IAR, Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991;83(1):61–5. [Crossref]

  • 92.

    Jones DE, Hollingsworth KG, Jakovljevic DG, Fattakhova G, Pairman J, et al. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. Eur J Clin Invest 2012;42(2):186–94. [Crossref]

  • 93.

    Mathew SJ, Mao X, Keegan KA, Levine SM, Smith ELP, et al.Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed 2009;22(3):251–8. [Crossref]

  • 94.

    Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed 2012;25(9):1073–87. [Crossref]

  • 95.

    Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, et al. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed 2010;23(6):643–50. [Crossref]

  • 96.

    Jason LA, Sunnquist M, Brown A, Evans M, Vernon S, et al. Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis. Fatigue 2013;2(1)40–56.

  • 97.

    Togo F, Lange G, Natelson BH, Quigley KS. Attention network test: Assessment of cognitive function in chronic fatigue syndrome. J Neuropsych 2015;9:1–9. [Crossref]

  • 98.

    Claypoole KH, Claypoole KH, Noonan C, Mahurin RK, Goldberg J, et al. A twin study of cognitive function in chronic fatigue syndrome: The effects of sudden illness onset. Neuropsychology 2007;21(4):507–13. [Crossref]

  • 99.

    Zinn ML, Zinn MA, Maldonado J, Norris J, Valencia I, et al. Cortical hypoactivation during resting state EEG suggests central nervous system pathology in patients with Chronic Fatigue Syndrome. Presentation: IACFS/ME, 11th Biennial Conference, March 2014, page 43. http://iacfsme.org/PDFS/2014Syllabus25.aspx.

  • 100.

    Zinn ML, Zinn MA, Maldonado J, Norris J, Valencia I, et al. EEG peak alpha frequency is associated with chronic fatigue syndrome: a case-control observational study. Presentation: IACFS/ME, 11th Biennial Conference, March 2014, page 42. http://iacfsme.org/PDFS/2014Syllabus25.aspx.

  • 101.

    Kishi AZ, Struzik ZR, Natelson BH, Togo F, Yamamoto Y. Dynamics of sleep stage transitions in healthy humans and patients with chronic fatigue syndrome. Am J Physiol – Reg I 2008;294(6):R1980–7.

  • 102.

    Neu D, Mairesse O, Verbanck P, Linkowski P, Le Bon O. Non-REM sleep EEG power distribution in fatigue and sleepiness. J Psychosom Res 2014;76(4):286–91. [Crossref]

  • 103.

    Van Hoof E, De Becker P, Lapp C, Cluydts R, De Meirleir K. Defining the occurrence and influence of alpha-delta sleep in chronic fatigue syndrome. Am J Med Sci 2007;333(2):78–84. [Crossref]

  • 104.

    Togo F, Natelson BH, Cherniack NS, FitzGibbons J, Garcon C, et al. Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia. Arthritis Res Ther. 2008;10(3):R56.

  • 105.

    Jackson ML, Bruck D. Sleep abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a review. J Clin Sleep Med 2012;8(6):719–28.

  • 106.

    Neu D, Mairesse O, Verbanck P, Le Bon O. Slow wave sleep in the chronically fatigued: power spectra distribution patterns in chronic fatigue syndrome and primary insomnia. Clin Neurophysiol 2015;126(10):1926–33. [Crossref]

  • 107.

    Unger, E. Measures of CFS in a multi-site clinical study. Paper read at FDA Scientific Drug Development Workshop, April 26, 2013, Washington, DC.

  • 108.

    Food and Drug Administration. The voice of the patient: Chronic fatigue syndrome and myalgic encephalomyelitis. Bethesda, MD: Center for Drug Evaluation and Research, FDA, 2013.

  • 109.

    Ickmans K, Meeus M, Kos D, Clarys P, Meersdom G, et al. Cognitive performance is of clinical importance, but is unrelated to pain severity in women with chronic fatigue syndrome. Clin Rheumy 2013;32(10):1475–85. [Crossref]

  • 110.

    Rowe PC, Calkins H. Neurally mediated hypotension and chronic fatigue syndrome. A J Med 1998;105(3A):15S–21.

  • 111.

    Rowe PC, Bou-Holaigah I, Kan JS, Calkins H. Is neurally mediated hypotension an unrecognized cause of chronic fatigue? Lancet 1995;345(8950):623–4. [Crossref]

  • 112.

    Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. J Am Med Ass 1995;274(12):961–7.

  • 113.

    Hollingsworth KG, Jones DE, Taylor R, Blamire AM, Newton JL. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Invest 2010;40(7):608–15. [Crossref]

  • 114.

    Costigan A, Elliott C, McDonald C, Newton JL. Orthostatic symptoms predict functional capacity in chronic fatigue syndrome: implications for management. QMJ: J Ass Phy 2010;103(8):589–95.

  • 115.

    Freeman R, Komaroff AL. Does the chronic fatigue syndrome involve the autonomic nervous system? Am Med 1997;102(4):357–64. [Crossref]

  • 116.

    Lerner AM, Lawrie C, Dworkin HS. Repetitively negative changing T waves at 24-h electrocardiographic monitors in patients with the chronic fatigue syndrome. Left ventricular dysfunction in a cohort. Chest 1993;104(5):1417–21. [Crossref]

  • 117.

    Streeten DH, Thomas D, Bell DS. The roles of orthostatic hypotension, orthostatic tachycardia and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med 2000;320:1–8. [Crossref]

  • 118.

    Hurwitz BE, Coryell VT, Parker M, Martin P, Laperriere A, et al. Chronic fatigue syndrome: Illness severity, sedentary lifestyle, blood volume and evidence of diminished cardiac function. Clin Sci 2010;118(2):125–35. [Crossref]

  • 119.

    Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, et al. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Ped 1999;135(4):494–9. [Crossref]

  • 120.

    Fuite J, Vernon SD, Broderick G. Neuroendocrine and immune network re-modeling in chronic fatigue syndrome: an exploratory analysis. Genomics 2008;92(6):393–9. [Crossref]

  • 121.

    Fletcher MA, Rosenthal M, Antoni M, Ironson G, Zeng XR, et al. Plasma neuropeptide Y: a biomarker for symptom severity in chronic syndrome. Behav Brain Funct 2010;6:76.

  • 122.

    Papadopoulos AS, Cleare AJ. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol 2011 Sep;8(1):22–32. [Crossref]

  • 123.

    De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, et al. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res 1999;31(1):18–21. [Crossref]

  • 124.

    Allain TJ, Bearn JA, Coskeran P, Jones J, Checkley A, et al. Changes in growth hormone, insulin, insulin like growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. Biol Psychiatry 1997 41(5):567–73. [Crossref]

  • 125.

    Sharpe M, Clements A, Hawton K, Young AH, Sargent P, et al. Increased prolactin response to Buspirone in chronic fatigue syndrome. J Affect Disord 1996;41(1):71–6. [Crossref]

  • 126.

    Bakheit AM, Behan PO, Watson WS, Morton JJ. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome. Acta Neurol Scand 1993;87(3):234–8.

  • 127.

    Boneva RS, Decker MJ, Maloney EM, Lin JM, Jones JF, et al. Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: a population-based study. Auton Neurosci 2007;137(1–2):94–101. [Crossref]

  • 128.

    Jason LA, Boulton A, Porter NS, Jessen T, Njoku MG, et al. Classification of myalgic encephalomyelitis/chronic fatigue syndrome by types of fatigue. Behav Med 2010;36(1):24–31. [Crossref]

  • 129.

    Jones DE, Hollingsworth KG, Jakovljevic DG, Fattakhova G, Pairman J, et al. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. Eur J Clin Invest 2012;42(2):186–94. [Crossref]

  • 130.

    Davenport TE, Stevens SR, VanNess MJ, Snell CR, Little T. Conceptual model for physical therapist management of chronic fatigue syndrome/myalgic encephalomyelitis. Phys Ther 2010;90(4):602–14. [Crossref]

  • 131.

    Stevens SR, Davenport TE. Functional outcomes of anaerobic rehabilitation in an individual with chronic fatigue syndrome: case report with 1-year follow-up. Bulletin of the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis 2010;18(3). http://iacfsme.org/ME-CFS-Primer-Education/Bulletins/Volume-18,-Issue-3-Fall-2010.aspx.

  • 132.

    Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev 2015. DOI: 10.1002/14651858.CD003200.pub3. [Crossref]

  • 133.

    Jason LA, Benton M. The impact of energy modulation on physical functioning and fatigue and severity among patients with ME/CFS. Patient Educ Couns 2009;77(2):237–41. [Crossref]

  • 134.

    Whistler T, Jones JF, Unger ER, Vernon SD. Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol. 2005;5(1):5.

  • 135.

    Jason L, Benton M, Torres-Harding S, Muldowney K. The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS. Patient Educ Couns 2009;77:237–41. [Crossref]

  • 136.

    Bested AC, Logan AC, Howe R. Hope and Help for Chronic Fatigue Syndrome and Fibromyalgia, 2nd ed. Nashville: Cumberland House, 2008:267pp.

  • 137.

    Taylor DJ, Roane BM. Treatment of insomnia in adults and children: a practice-friendly review of research. J Clinical Psychology 2010;66(11):1137–47. [Crossref]

  • 138.

    Carrier J, Dumont M. Sleep propensity and sleep architecture after bright light exposure at three different times of day. J Sleep Res 1995;4(4):202–11. [Crossref]

  • 139.

    Morriss RK, Wearden AJ. Screening instruments for psychiatric morbidity in chronic fatigue syndrome. J R Soc Med 1998;91(7):365–8.

  • 140.

    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiat Scand 1983;67(6):361–70. [Crossref]

  • 141.

    Friedberg F, Jason LA. Understanding chronic fatigue syndrome: An empirical guide to assessment and treatment. Washington, D.C.: American Psychological Association, 1998. Chapter 7: Differential diagnosis in CFS; p. 99–118.

  • 142.

    Friedberg F. Fibromyalgia and chronic fatigue syndrome: Seven proven steps to less pain and more energy. Oakland, CA: New Harbinger, 2006.

  • 143.

    Ray C, Jefferies S, Weir WR. Life-events and the course of chronic fatigue syndrome. Brit J Med Psychol 1995;68:323–31. [Crossref]

  • 144.

    Friedberg F. Chronic fatigue syndrome, fibromyalgia, and related illnesses: a clinical model of assessment and intervention. J Clinical Psychology 2010;6:641–65.

  • 145.

    Maes M, Leunis JC. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett 2008;29(6):902–10.

  • 146.

    Berkovitz S, Ambler G, Jenkins M, Thurgood S. Serum 25-hydroxy vitamin D levels in chronic fatigue syndrome: a retrospective survey. Int J Vitam Nutr Res 2009;79(4):250–4. [Crossref]

  • 147.

    Regland B, Andersson M, Abrahamsson L, Bagby J, Dyrehag LE, et al. Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. Scand J Rheumatol 1997;26(4):301–7. [Crossref]

  • 148.

    Puri BK. The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. Prostaglandins Leukot Essent Fatty Acids 2004;70(4):399–401.

  • 149.

    Puri BK. Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J Clin Pathol 2007;60:122–4.

  • 150.

    Prasad AS. Zinc: mechanisms of host defense. J Nutr 2007;137(5):1345–9.

  • 151.

    Maes M. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 2009;30(4):470–6.

  • 152.

    Morris G, Anderson G, Berk M, Maes M. Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications. Mol Neurobiol 201348(3):883–903.

  • 153.

    Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. [Rev] Brain Beh Imm 2012;26(1):24–31. [Crossref]

  • 154.

    Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18 Suppl 1:S88–95. [Crossref]

  • 155.

    Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, et al. Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS ONE 2012;7(3):e31334.

  • 156.

    Magill MK, Suruda A. Multiple chemical sensitivity syndrome. Am Fam Phys 1998;58(3):721–8.

  • 157.

    Marshall L, Bested AJM, Kerr K, Bray R. Environmental Sensitivities-Multiple Chemical Sensitivities Status Report. Toronto, Canada, 2011. http://www.womenshealthmatters.ca/assets/legacy/wch/pdfs/ESMCSStatusReportJune22011.pdf.

  • 158.

    Alraek T, Lee MS, Choi TY, Cao H, Liu J. Complementary and alternative medicine for patients with chronic fatigue syn-drome: a systematic review. BMC Compl Alt Med 2011;11:87.

  • 159.

    Porter NS, Jason LA, Boulton A, Bothne N, Coleman B. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J Alt Compl Med 2010;16(3):235–49. [Crossref]

  • 160.

    Jason LA, Richman JA. How science can stigmatize: The case of chronic fatigue syndrome. J Chronic Fatigue Synd 2008;14(4):85–103. [Crossref]

  • 161.

    Jason L, Sunnquist M, Brown A, McManimen S, Furst J. Reflections on the IOM’s systemic exertion intolerance disease. Pol Arch Med Wewn 2015 pii: AOP_15_067.

About the article

Corresponding author: Dr. Alison C. Bested, 107-1265 Morningside Ave, Toronto, Ontario, Canada, E-mail: ; and Department of Medicine, University of British Columbia, Vancouver, BC, Canada


Received: 2015-08-17

Accepted: 2015-11-02

Published Online: 2015-11-27

Published in Print: 2015-12-01


Citation Information: Reviews on Environmental Health, ISSN (Online) 2191-0308, ISSN (Print) 0048-7554, DOI: https://doi.org/10.1515/reveh-2015-0026. Export Citation

Supplementary Article Materials

Comments (0)

Please log in or register to comment.
Log in